Quintiles

Quintiles in Alliances with AstraZeneca, Eisai

Wednesday, November 4, 2009 07:21 AM

Quintiles has entered into a strategic alliance with AstraZeneca. The contract research organization (CRO)-clinical pharmacology alliance with AstraZeneca was formed to deliver the sponsor’s clinical pharmacology studies across multiple therapy areas and around the globe.

More... »

Quintiles, Cerner Join to Improve Late Phase Research Efficiency

Friday, October 16, 2009 08:11 AM

Quintiles, the market-leading contract research organization (CRO) and Cerner, a global supplier of healthcare solutions and electronic health record (EHR) technology, signed an agreement that will provide biopharmaceutical sponsors with research and technology services for improving post-marketing research. 

More... »

Sage Bionetworks Receives Quintiles Donation

Wednesday, October 14, 2009 07:41 AM

Sage Bionetworks, a not-for-profit organization established to develop an open-access genomic platform for use in drug discovery, has received a major donation from Quintiles, a contract research organization (CRO).

More... »

Quintiles Expands with New Facility in Scotland

Monday, October 5, 2009 09:55 AM

Quintiles has boosted its capacity to support clinical trials across Europe by opening an expanded regional facility, including an 80,000-square-foot central laboratory, near Edinburgh, Scotland. 

More... »

Quintiles Aims to Increase Patient Enrollment through South Africa Partnership

Monday, September 28, 2009 06:06 AM

Quintiles added another partner to its Prime Site program—an initiative to accelerate drug development and gain access to more patients.

More... »

LabConnect Hires Former Quintiles Exec to be COO

Friday, August 28, 2009 07:32 AM

LabConnect, a provider of central laboratory services to the clinical trial industry, appointed former Quintiles executive Frank Morrow, Ph.D., as its chief operating officer.

More... »

Kendle Reports 50% Income Drop, Suspends Guidance for 2009

Thursday, August 6, 2009 08:04 AM

Kendle’s net income was cut almost 50% in the second quarter 2009 with income dropping to $3.2 million, or $0.21 per diluted share, compared with net income of $6.3 million, or $0.42 per diluted share in Q2 2008. Net revenues for the quarter were $107.4 million, down from $127 million during the same period last year.

More... »

CenterWatch Monthly May 2009

Friday, May 1, 2009 11:00 AM

U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009

More... »

Quintiles to Open Phase I Unit in India

Monday, February 9, 2009 08:00 AM

Contract research organization Quintiles is partnering with India’s largest hospital group to open Quintiles’ first phase I clinical trial unit in India.

More... »

Quintiles Plans Phase I Unit in India

Wednesday, January 28, 2009 08:00 AM

Contract research organization (CRO) Quintiles is partnering with Apollo Hospitals Group in India to open a phase I clinical trial unit in Hyderabad, India.

More... »